secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-044805
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut
----------------------------------------------------------------------------

- Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.
- Q4 operating loss $17.1M vs $25.7M YoY, includes $4.6M restructuring and financing costs.
- Q4 gross margin 45% vs 78% YoY; full-year 67%; expects margin expansion in 2025.
- Sales resumed in France Feb 12, 2025; positive AUDACITY FDA trial readout; next-gen balloon launched.
- Cash $15.4M at Dec 31, 2024; recent financings expected to fund through potential FDA approval in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025044805/0000950170-25-044805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000095017025044805/alur-20250326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer